AU2021305193A1 - Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer - Google Patents
Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer Download PDFInfo
- Publication number
- AU2021305193A1 AU2021305193A1 AU2021305193A AU2021305193A AU2021305193A1 AU 2021305193 A1 AU2021305193 A1 AU 2021305193A1 AU 2021305193 A AU2021305193 A AU 2021305193A AU 2021305193 A AU2021305193 A AU 2021305193A AU 2021305193 A1 AU2021305193 A1 AU 2021305193A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- alkyl
- optionally substituted
- independently
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063049556P | 2020-07-08 | 2020-07-08 | |
| US63/049,556 | 2020-07-08 | ||
| PCT/US2021/040736 WO2022011043A2 (en) | 2020-07-08 | 2021-07-07 | Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021305193A1 true AU2021305193A1 (en) | 2023-02-09 |
Family
ID=79553738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021305193A Pending AU2021305193A1 (en) | 2020-07-08 | 2021-07-07 | Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230248835A1 (https=) |
| EP (1) | EP4178574A4 (https=) |
| JP (1) | JP2023533961A (https=) |
| CN (1) | CN115916342A (https=) |
| AU (1) | AU2021305193A1 (https=) |
| CA (1) | CA3184740A1 (https=) |
| WO (1) | WO2022011043A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3996715A4 (en) * | 2019-07-08 | 2024-01-03 | Purdue Research Foundation | COMPOUNDS AND METHODS FOR TREATING AND PREVENTING FIBROTIC DISEASES AND CANCER |
| EP4271378A4 (en) * | 2021-01-04 | 2026-03-11 | Purdue Research Foundation | METHODS FOR IMPROVING MODIFIED CELL THERAPIES IN CANCER TREATMENT |
| EP4683669A2 (en) * | 2023-03-23 | 2026-01-28 | Purdue Research Foundation | Combinations and methods for enhancing checkpoint inhibitor therapies in cancer treatment |
| CN119215159A (zh) * | 2024-09-24 | 2024-12-31 | 深圳市格茵莱生物科技有限公司 | 树突状细胞多抗原负载免疫治疗方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0413558A (pt) * | 2003-08-12 | 2006-10-17 | 3M Innovative Properties Co | compostos contendo imidazo substituìdo por hidroxilamina |
| CA2547020C (en) * | 2003-11-25 | 2014-03-25 | 3M Innovative Properties Company | 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier |
| EP1699788A2 (en) * | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
| WO2005094531A2 (en) * | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| JP2007530579A (ja) * | 2004-06-10 | 2007-11-01 | スリーエム イノベイティブ プロパティズ カンパニー | アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン |
| EP1851224A2 (en) * | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinolines |
| HRP20120895T1 (hr) * | 2007-05-08 | 2012-11-30 | Astrazeneca Ab | Imidazokinolini sa imuno-modulacijskim svojstvima |
| KR102685007B1 (ko) * | 2015-08-31 | 2024-07-12 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 구아니딘 치환된 이미다조[4,5-c] 고리 화합물 |
| DE212016000029U1 (de) * | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| AU2017271550B2 (en) * | 2016-05-25 | 2023-11-02 | Endocyte, Inc. | Method of treating cancer by targeting myeloid-derived suppressor cells |
| BR112020004505A2 (pt) * | 2017-09-06 | 2020-09-15 | BioNTech SE | imidazoquinolinas substituídas como agonistas de tlr7 |
| WO2020023680A1 (en) * | 2018-07-24 | 2020-01-30 | Torque Therapeutics, Inc. | Tlr7/8 agonists and liposome compositions |
| AU2019335366A1 (en) * | 2018-09-07 | 2021-03-25 | Birdie Biopharmaceuticals, Inc. | Imidazoquinoline compounds and uses thereof |
| CA3125133A1 (en) * | 2018-12-26 | 2020-07-02 | Birdie Biopharmaceuticals, Inc. | Immune modulatory combinations and methods for treating cancers |
| WO2020236253A1 (en) * | 2019-05-20 | 2020-11-26 | Massachusetts Institute Of Technology | Boronic ester prodrugs and uses thereof |
-
2021
- 2021-07-07 US US18/004,656 patent/US20230248835A1/en active Pending
- 2021-07-07 JP JP2023500997A patent/JP2023533961A/ja active Pending
- 2021-07-07 WO PCT/US2021/040736 patent/WO2022011043A2/en not_active Ceased
- 2021-07-07 CA CA3184740A patent/CA3184740A1/en active Pending
- 2021-07-07 EP EP21837283.7A patent/EP4178574A4/en active Pending
- 2021-07-07 AU AU2021305193A patent/AU2021305193A1/en active Pending
- 2021-07-07 CN CN202180051458.8A patent/CN115916342A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022011043A3 (en) | 2022-03-03 |
| WO2022011043A2 (en) | 2022-01-13 |
| EP4178574A2 (en) | 2023-05-17 |
| JP2023533961A (ja) | 2023-08-07 |
| EP4178574A4 (en) | 2024-04-10 |
| CA3184740A1 (en) | 2022-01-13 |
| CN115916342A (zh) | 2023-04-04 |
| US20230248835A1 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021305193A1 (en) | Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer | |
| US9908880B2 (en) | Substituted imidazoquinolines | |
| AU2007257423B8 (en) | Purine analogs | |
| ES3060380T3 (en) | Immunomodulator | |
| CN113195469B (zh) | 含氮并环化合物、其制备方法及用途 | |
| CN114599360A (zh) | 4-氨基-咪唑并喹啉化合物及其用途 | |
| CN121449666A (zh) | Sting促效剂 | |
| CN119604504A (zh) | 一类双并环化合物、其制备方法及用途 | |
| US10988457B2 (en) | TLR inhibitors | |
| US20210253613A1 (en) | Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | |
| CA3145908A1 (en) | Compounds and methods for the treatment and prevention of fibrotic disease states and cancer | |
| CN119371430A (zh) | 喜树碱类小分子及其抗体药物偶联物、制备方法和应用 | |
| HK1152238B (en) | Novel substituted imidazoquinolines |